{
    "clinical_study": {
        "@rank": "97287", 
        "arm_group": {
            "arm_group_label": "Treatment (vorinostat and surgery)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies vorinostat before surgery in treating patients with\n      triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking\n      some of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery\n      may make the tumor smaller and reduce the amount of normal tissue that needs to be removed"
        }, 
        "brief_title": "Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stage II Breast Cancer", 
            "Stage IIIA Breast Cancer", 
            "Triple-negative Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the ability of histone deacetylase (HDAC) inhibition using suberoylanilide\n      hydroxamic acid (SAHA) (vorinostat) to induce expression of the estrogen receptor (ER) and\n      progesterone receptor (PR) genes in solid human triple negative invasive breast cancer.\n\n      OUTLINE:\n\n      Patients receive vorinostat 400 mg daily orally (PO) on days 1-21 followed by surgery within\n      14 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Resectable tumor measuring 2cm or more\n\n          -  Histologically documented, newly diagnosed, triple negative invasive breast cancer\n             characterized by 0% immunohistochemistry (IHC) nuclear staining for ER-alpha, 0% IHC\n             nuclear staining for PR-alpha, and no amplification of human epidermal growth factor\n             receptor 2 (HER2)/neu by fluorescent in situ hybridization (FISH) using institutional\n             standard; standard IHC assays for ER and PR use antibodies to ER-alpha and PR-alpha\n             and PR-beta\n\n          -  Southwest Oncology Group (SWOG) performance status of less than or equal to 1\n\n          -  Absolute neutrophil count (ANC) >= 1500/uL\n\n          -  Hemoglobin (Hgb) >= 9 g/dL\n\n          -  Platelets >= 100,000/uL\n\n          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and\n             alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =< 2.5 x\n             upper limit of normal (ULN) or =< 5.0 x ULN in patients with liver metastases\n\n          -  Creatinine =< 2.0 mg/dL or calculated creatinine clearance >= 50 ml/min\n\n          -  Albumin >= 3 g/dL\n\n          -  Potassium >= lower limit normal (LLN)\n\n          -  Phosphorous >= LLN\n\n          -  Calcium >= LLN\n\n          -  Magnesium > LLN\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test\n             performed within 7 days prior to start of treatment\n\n          -  Accessible for treatment and follow-up\n\n          -  Written informed consent prior to study entry\n\n        Exclusion Criteria:\n\n          -  HER2/neu amplification by FISH\n\n          -  Concurrent neoadjuvant anti-cancer treatment with chemotherapy, endocrine therapy,\n             biologically targeted therapy or radiotherapy\n\n          -  Known hypersensitivity to SAHA\n\n          -  Preexisting hepatic impairment or renal impairment\n\n          -  Intent to receive additional neoadjuvant therapy prior to surgery\n\n          -  Concurrent use of an HDAC inhibitor or hydralazine\n\n          -  Known diagnosis of human immunodeficiency virus (HIV) infection\n\n          -  Major surgery < 4 weeks prior to starting study drug\n\n          -  Pregnant or breastfeeding or female of reproductive potential not using an effective\n             method of birth control\n\n          -  Other concurrent severe, uncontrolled infection or intercurrent illness, including\n             but not limited to ongoing or active infection or psychiatric illness/social\n             situations that would limit compliance with study requirements\n\n          -  Prior antiestrogens (selective estrogen receptor modulator [SERM] or aromatase\n             inhibitors) within 6 months of study entry\n\n          -  Underlying medical, psychiatric or social conditions that would preclude patient from\n             receiving treatment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695057", 
            "org_study_id": "1B-10-10", 
            "secondary_id": "NCI-2012-01612"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (vorinostat and surgery)", 
                "description": "Given PO", 
                "intervention_name": "vorinostat", 
                "intervention_type": "Drug", 
                "other_name": [
                    "L-001079038", 
                    "SAHA", 
                    "suberoylanilide hydroxamic acid", 
                    "Zolinza"
                ]
            }, 
            {
                "arm_group_label": "Treatment (vorinostat and surgery)", 
                "description": "Undergo surgery", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (vorinostat and surgery)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vorinostat"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 27, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Agustin Garcia", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients who achieve sufficient deacetylation of ER and PR will be estimable with a standard error no greater than +/- 0.05. The proportion of patients who exhibit a sufficient change in ER or PR expression can be estimated with similar precision. In addition, paired t-tests and McNamara\u00c3\u00a2s test will be used to evaluate whether the effect of vorinostat on deacetylation status or gene expression differs between ER or PR, and linear regression analysis will be used to evaluate the association between deacetylation changes and corresponding expression changes in ER and PR genes.", 
            "measure": "Combined PR/ER response", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695057"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The toxicities observed will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity (by NCI Common Toxicity Criteria v4.0 and nadir or maximum values for the laboratory measures), time of onset (i.e. week of treatment), duration, and reversibility or outcome.", 
            "measure": "Grade 3 or 4 toxicities using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "Within 3 days prior to surgery"
        }, 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Lack of funding"
    }
}